Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BANZEL vs ALPRAZOLAM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BANZEL (rufinamide) is a triazole derivative that modulates the activity of voltage-gated sodium channels. It prolongs the inactive state of sodium channels, thereby stabilizing neuronal membranes and inhibiting the repetitive firing of action potentials.
Positive allosteric modulator of GABA-A receptors; enhances GABA inhibitory neurotransmission by binding to benzodiazepine site on GABA-A receptor, increasing chloride ion conductance.
Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in patients 1 year of age and older (FDA-approved),Off-label: Adjunctive therapy for partial-onset seizures, generalized tonic-clonic seizures, and other refractory epilepsies
Generalized anxiety disorder,Panic disorder with or without agoraphobia,Anxiety (off-label),Insomnia (off-label),Chemotherapy-induced nausea and vomiting (off-label),Premenstrual dysphoric disorder (off-label)
400 mg orally twice daily, titrated by 400 mg increments every 2 weeks to a maximum of 1600 mg twice daily.
0.25-0.5 mg orally 3 times daily; maximum 4 mg/day in divided doses.
Terminal elimination half-life is approximately 6-10 hours in adults; in pediatric patients, it is shorter (~3-6 hours). Steady-state is reached within 1-2 days.
12-15 hours (mean ~13 hours); prolonged in elderly (up to 19 hours) and hepatic impairment (up to 20-30 hours); clinical context: allows once- to twice-daily dosing, but risk of accumulation with high doses or in vulnerable populations
Primarily hydrolyzed by carboxylesterases in the liver to inactive metabolites (CGP 47292). Minor metabolism via CYP450 enzymes (CYP2E1, CYP3A4, CYP1A2, CYP2B6, CYP2C9, CYP2C19) but not significantly.
Primarily hepatic via CYP3A4; major metabolites are alpha-hydroxyalprazolam (active) and 4-hydroxyalprazolam (inactive).
Primarily renal: approximately 66% of the dose excreted in urine (30% as unchanged rufinamide, 70% as inactive metabolites). Fecal excretion: ~4%. No significant biliary excretion.
Renal (approximately 80% as metabolites, <20% unchanged); fecal (minor, ~7%)
Approximately 34% bound to plasma proteins, primarily albumin.
80% (primarily to albumin, minor to α1-acid glycoprotein)
Apparent volume of distribution is approximately 0.7-1.0 L/kg, indicating distribution primarily into total body water.
0.8 L/kg (range 0.6-1.2 L/kg); clinical meaning: moderate tissue distribution, reflects lipophilicity; higher Vd in obesity
Absolute oral bioavailability is approximately 85% (high). Food increases Cmax and AUC by about 30-40%, but this is not considered clinically significant for dosing.
Oral: 90% (immediate-release); extended-release: approximately 90% relative to immediate-release; sublingual: approximately 75-80% of oral
Cr Cl < 30 m L/min: not recommended. Cr Cl 30-50 m L/min: maximum dose 400 mg twice daily. Cr Cl > 50 m L/min: no adjustment.
GFR 10-50 m L/min: reduce dose by 50%; GFR <10 m L/min: use with caution, reduce dose by 50% or consider alternative.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: start 200 mg twice daily, maximum 400 mg twice daily. Child-Pugh Class C: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Age ≥4 years: based on body weight. Starting dose: 10 mg/kg/day divided twice daily, titrate weekly by increments of 10 mg/kg/day to target maintenance 40 mg/kg/day (max 3200 mg/day). Max single dose: 1600 mg twice daily.
Not FDA-approved for <18 years; limited data: 0.125 mg/kg/dose orally 3 times daily (max 0.02 mg/kg/dose) for panic disorder in adolescents.
No specific dose adjustment, but consider age-related renal impairment; monitor Cr Cl.
Start with 0.25 mg orally 2-3 times daily; increase slowly due to increased sensitivity and risk of falls; maximum 2 mg/day.
None
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate.
May shorten QT interval; use caution with other drugs that shorten QT interval. Increased risk of suicidal thoughts/behavior. Monitor for hypersensitivity reactions (including DRESS). Central nervous system depression (dizziness, somnolence, ataxia). May decrease efficacy of hormonal contraceptives. Withdrawal seizures if abruptly discontinued. Dose adjustment needed in severe hepatic impairment.
Risk of abuse, misuse, and addiction; dependence and withdrawal reactions; respiratory depression; worsening of depression or suicidal ideation; use in patients with acute narrow-angle glaucoma; impaired motor and cognitive performance; risk of severe allergic reactions.
Familial short QT syndrome (due to QT interval shortening). Hypersensitivity to rufinamide or any of its components.
Concurrent use with ketoconazole or itraconazole; hypersensitivity to benzodiazepines; acute narrow-angle glaucoma; severe hepatic impairment; pregnancy (especially first trimester) and breastfeeding.
BANZEL should be taken with food to increase bioavailability (Cmax increases by approximately 40% and AUC by 50% compared to fasting). Avoid grapefruit juice as it may alter drug metabolism. No other food interactions are documented.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing alprazolam levels and risk of toxicity. Avoid alcohol. No other significant food interactions.
First trimester: Increased risk of major congenital malformations, including neural tube defects, craniofacial defects, and cardiac anomalies. Second and third trimesters: Risk of intrauterine growth restriction, neurodevelopmental delay, and hemorrhagic disease of the newborn due to vitamin K deficiency.
First trimester: Associated with increased risk of cleft lip/palate (OR 2.0); avoid if possible. Second/third trimester: Risk of benzodiazepine withdrawal or floppy infant syndrome (hypotonia, respiratory depression, feeding difficulties) with chronic high-dose use. Late third trimester: Risk of neonatal withdrawal syndrome.
Rufinamide is excreted in human milk. The milk-to-plasma ratio is approximately 0.3. Breastfeeding is not recommended due to potential adverse effects in the infant, including somnolence, poor feeding, and weight loss.
Excreted into breast milk; M/P ratio approximately 0.3-0.5. Relative infant dose ~2-3% of maternal weight-adjusted dose. Clinical significance: low but may cause sedation, poor feeding, or withdrawal in neonates. Use caution, monitor infant for lethargy and weight gain.
Pregnancy may reduce serum concentrations due to increased clearance and volume of distribution. Monitor trough levels and adjust dose to maintain therapeutic efficacy. Postpartum, monitor for toxicity as levels may rise.
Increased clearance and volume of distribution in pregnancy may require dose up-titration. Monitor clinical response; consider increasing dose by 20-50% in second and third trimesters. Avoid abrupt discontinuation; taper if needed. Use lowest effective dose for shortest duration.
BANZEL (rufinamide) is an antiepileptic drug indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients ≥1 year. Titrate slowly over 2-3 weeks to reduce risk of adverse effects. Monitor for shortened QT interval; contraindicated in familial short QT syndrome. Dose adjustments needed in severe hepatic impairment. May decrease efficacy of oral contraceptives containing ethinyl estradiol. Administer with food to enhance absorption.
Alprazolam is a short-acting benzodiazepine with a rapid onset. Due to its high potency and short half-life, it carries a high risk of dependence and withdrawal. Avoid in patients with narrow-angle glaucoma, severe respiratory insufficiency, or myasthenia gravis. Use with caution in patients with history of substance abuse. Taper gradually to prevent rebound anxiety and seizures. Onset of action is 15-30 min orally; peak effect at 1-2 hours.
Take BANZEL exactly as prescribed with food to improve absorption.,Do not stop taking BANZEL suddenly; taper under medical supervision to avoid withdrawal seizures.,Inform your doctor if you have a heart condition, especially short QT syndrome.,Use effective contraception if applicable; BANZEL may reduce efficacy of oral contraceptives.,Monitor for dizziness, drowsiness, or coordination problems; avoid driving until you know how BANZEL affects you.,Report any unusual tiredness, fatigue, or signs of liver injury (yellowing skin/eyes, dark urine) immediately.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other central nervous system depressants as they can cause severe sedation and respiratory depression.,Do not drive or operate heavy machinery until you know how alprazolam affects you; it may cause drowsiness or dizziness.,Do not stop abruptly; withdrawal symptoms can include anxiety, insomnia, seizures, and life-threatening reactions.,Store at room temperature away from moisture and heat. Keep out of reach of children.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Report any worsening of depression or suicidal thoughts immediately.
No interactions on record
"Alprazolam, a benzodiazepine, potentiates the central nervous system (CNS) depressant effects of tetracaine, an ester-type local anesthetic. This additive or synergistic interaction can lead to excessive sedation, respiratory depression, and hypotension, particularly in elderly or debilitated patients. Concurrent use may also increase the risk of seizures due to tetracaine's proconvulsant activity at high doses, which is compounded by alprazolam's withdrawal-associated seizure risk."
"Co-administration of alprazolam, a benzodiazepine, with indinavir, a potent CYP3A4 inhibitor, significantly increases alprazolam's serum concentration and half-life via reduced hepatic metabolism, leading to excessive sedation, respiratory depression, and impaired psychomotor function. Conversely, indinavir levels may be modestly increased due to competition for metabolism. This interaction poses a risk of severe central nervous system depression and should be avoided if possible."
"Concurrent use of alprazolam, a benzodiazepine with central nervous system depressant effects, and proparacaine, a topical ophthalmic anesthetic that can be systemically absorbed, may lead to additive CNS depression. This interaction can manifest as increased sedation, dizziness, confusion, or respiratory depression, especially in patients with compromised respiratory function or those receiving high doses of either agent. Clinicians should exercise caution when combining these drugs due to the potential for enhanced adverse effects."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BANZEL vs ALPRAZOLAM, answered by our medical review team.
BANZEL is a Anticonvulsant that works by BANZEL (rufinamide) is a triazole derivative that modulates the activity of voltage-gated sodium channels. It prolongs the inactive state of sodium channels, thereby stabilizing neuronal membranes and inhibiting the repetitive firing of action potentials.. ALPRAZOLAM is a Benzodiazepine that works by Positive allosteric modulator of GABA-A receptors; enhances GABA inhibitory neurotransmission by binding to benzodiazepine site on GABA-A receptor, increasing chloride ion conductance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BANZEL and ALPRAZOLAM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BANZEL is: 400 mg orally twice daily, titrated by 400 mg increments every 2 weeks to a maximum of 1600 mg twice daily.. The standard adult dose of ALPRAZOLAM is: 0.25-0.5 mg orally 3 times daily; maximum 4 mg/day in divided doses.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BANZEL and ALPRAZOLAM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BANZEL is classified as Category C. First trimester: Increased risk of major congenital malformations, including neural tube defects, craniofacial defects, and cardiac anomalies. Second and third trimesters: Risk of . ALPRAZOLAM is classified as Category D/X. First trimester: Associated with increased risk of cleft lip/palate (OR 2.0); avoid if possible. Second/third trimester: Risk of benzodiazepine withdrawal or floppy infant syndrome. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.